Evidence map›Paper›PMID 29845015›Full record

ArticleMolecular genetics and metabolism reports2018

Risks of long-term port use in enzyme replacement therapy for lysosomal storage disorders.

Christian J Hendriksz, Paul Harmatz, Roberto Giugliani, Jane Roberts, G Suren Arul

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular genetics and metabolism reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 5 institutions in 4 countries.

Christian J HendrikszSalford Royal Foundation NHS Trust, Manchester, UK.
Paul HarmatzUCSF Benioff Children's Hospital Oakland, Oakland, CA, USA.
Roberto GiuglianiMedical Genetics Service, HCPA, Department of Genetics, UFRGS and INAGEMP, Porto Alegre, Brazil.
Jane RobertsSt. Mary's Hospital, Manchester, UK.
G Suren ArulBirmingham Children's Hospital, Birmingham, UK.
Birmingham Children's Hospital · GBSalford Royal NHS Foundation Trust · GBSt. Mary's Hospital · GBUCSF Benioff Children's Hospital · USUniversidade Federal do Rio Grande do Sul · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Totally implantable vascular access devices (TIVADs) are commonly used in conjunction with enzyme replacement therapy (ERT) for lysosomal storage disorders (LSDs). This case series describes potential complications associated with long-term TIVAD use, such as compromise of skin integrity, infection, or port failures. Best practices and skilled specialists are essential for minimizing complications from long-term TIVAD use for ERT.

Indexed as

Enzyme replacement therapyLysosomal storage disorderMucopolysaccharidosisTotally implantable venous access device

Identifiers

PMID29845015
PMCPMC5966583
OpenAlexW2791748613

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.